Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | CPB1 | P15086 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13897436 | 0.84 | NPSR1 (0.59) | NPSR1MAPTALDH1A1L3MBTL1LMNA | |
| SCHEMBL7315808 | 0.84 | L3MBTL1 (0.76) | NPSR1MAPTL3MBTL1LMNATP53 | |
| SCHEMBL7315799 | 0.84 | L3MBTL1 (0.76) | NPSR1MAPTL3MBTL1LMNATP53 | |
| SCHEMBL15564173 | 0.83 | GAA (0.50) | NPSR1MAPTALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL5244004 | 0.81 | NPSR1 (0.69) | NPSR1MAPTALDH1A1LMNATSHR | |
| SCHEMBL2552838 | 0.80 | HTR2A (0.62) | HTR2ACPB1KCNH2MEN1KMT2A | |
| SCHEMBL32679522 | 0.77 | KMT2A (0.72) | NPSR1MAPTALDH1A1POLBL3MBTL1 | |
| SCHEMBL5472868 | 0.77 | ALDH1A1 (0.69) | ALDH1A1LMNATP53SMN1; SMN2MEN1 | |
| SCHEMBL28217829 | 0.77 | MAPT (1.00) | NPSR1MAPTALDH1A1POLBL3MBTL1 | |
| SCHEMBL2838903 | 0.77 | ALDH1A1 (0.68) | ALDH1A1POLBLMNASMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100010007-A1 | PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | ASTRAZENECA AB (SE) | 2010-01-14 | — | — | US | disclosed |
| US-7615555-B2 | Piperidine derivatives as modulators of chemokine receptor CCR5 | ASTRAZENECA AB (SE) | 2009-11-10 | — | — | US | disclosed |
| US-7361668-B2 | Quinuclidine derivatives processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors | UCB, S.A. (BE) | 2008-04-22 | — | — | US | disclosed |
| CN-100381423-C | Novel piperidine derivatives as modulators of chemokine receptor CCR5 | ASTRAZENECA AB (SE) | 2008-04-16 | — | — | CN | disclosed |
| US-20080021038-A1 | Novel Piperidine/8-Azabicyclo [3.2.1.] Octan Derivatives As Modulators Of Chemokine Receptor Ccr5 | TUCKER HOWARD | 2008-01-24 | — | — | US | disclosed |
| US-20080021038-A1 | Novel Piperidine/8-Azabicyclo [3.2.1.] Octan Derivatives As Modulators Of Chemokine Receptor Ccr5 | TUCKER HOWARD | 2008-01-24 | — | — | US | disclosed |
| US-20080021038-A1 | Novel Piperidine/8-Azabicyclo [3.2.1.] Octan Derivatives As Modulators Of Chemokine Receptor Ccr5 | TUCKER HOWARD | 2008-01-24 | — | — | US | disclosed |
| EP-1648871-B1 | PIPERIDINE OR 8-AZA-BICYCLO 3.2.1 OCT-3-YL DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2007-10-17 | — | — | EP | disclosed |
| EP-1648871-B1 | PIPERIDINE OR 8-AZA-BICYCLO 3.2.1 OCT-3-YL DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2007-10-17 | — | — | EP | disclosed |
| CN-101006057-A | Novel piperidine/8-azabicyclo [3.2.1] octan derivatives as moduilators of chemokine receptor CCR5 | ASTRAZENECA AB (SE) | 2007-07-25 | — | — | CN | disclosed |
| WO-2005101989-A2 | PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | WO | disclosed |
| EP-1572650-A1 | NOVEL PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | AstraZeneca AB (SE) | 2005-09-14 | — | — | EP | disclosed |
| EP-1572683-A1 | NOVEL PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | AstraZeneca AB (SE) | 2005-09-14 | — | — | EP | disclosed |
| WO-2005009959-A1 | PIPERIDINE DERIVATIVES AS CCR5 RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2005-02-03 | — | — | WO | disclosed |
| US-20050020660-A1 | Quinuclidine derivatives processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors | UCB, S.A. (BE) | 2005-01-27 | — | — | US | disclosed |
| WO-2005007629-A1 | PIPERIDINE OR 8-AZA-BICYCLO[3.2.1]OCT-3-YL DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2005-01-27 | — | — | WO | disclosed |
| EP-1438309-A1 | QUINUCLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS M2 AND/OR M3 MUSCARINIC RECEPTOR INHIBITORS | UCB, S.A. (BE) | 2004-07-21 | — | — | EP | disclosed |
| WO-2004056808-A1 | NOVEL PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | ASTRAZENECA AB (SE) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004056773-A1 | NOVEL PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | ASTRAZENECA AB (SE) | 2004-07-08 | — | — | WO | disclosed |
| WO-2003033495-A1 | QUINUCLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS M2 AND/OR M3 MUSCARINIC RECEPTOR INHIBITORS | UCB, S.A. (BE) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010007-A1 | PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | CCR5, CCR2, CXCR3 | NPSR1 133/4885MAPT 3920/4885ALDH1A1 1094/4885 |
| US-20050020660-A1 | Quinuclidine derivatives processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors | CHRM2, CHRM3, CHRM1 | NPSR1 117/4885MAPT 2250/4885ALDH1A1 727/4885 |
| US-20080021038-A1 | Novel Piperidine/8-Azabicyclo [3.2.1.] Octan Derivatives As Modulators Of Chemokine Receptor Ccr5 | CCR5, CXCR1, CCR2 | NPSR1 161/4885MAPT 4553/4885ALDH1A1 939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.